London, United Kingdom, May 22, 2017 --(PR.com
)-- With just 3 weeks to go, SMi Group have released an attendee list featuring a global audience of regulatory bodies, scientists, medical device experts and industry leaders for In Vitro Diagnostics 2017, set to take place in Central London this June. The international gathering emphasises a growing IVD market which is expected to reach $122.9bn by 2017. *
Nations confirmed to attend include Belgium, France, Germany, Netherlands United Kingdom, UAE & USA.
A snapshot of organisations confirmed to join include:
Arkray Inc, Berlin Heart A G, BSI, Cytocell Ltd, Dekra, GS1, Immucor, IQ Products, Lifescan (J&J), LNE/G-MED, LRQA, Meridian Bioscience, MET, MHRA, Ortho Clinical Diagnostics, Procorre, Qarad Bvba, Qserve Consultancy, SPD Ltd., Tuv Rheinland, TUV SUD AB, UL International and more.
View 2017 Attendee List
The agenda will address questions such as:
How can IVD manufacturers prepare for the new IVD regulation?
How the change in classifications will impact the industry.
What are the best strategies and approaches to meeting the requirements for clinical evidence?
For those looking to attend there is currently a £100 early bird saving available online.
Further information including a detailed agenda and full speaker line-up is available at http://www.in-vitro-diagnostics.co.uk/ein
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: firstname.lastname@example.org
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk